Coming soon: Updated website and features - Click here for more information

Orexo: Zubsolv Rx Data - March

The market share for Zubsolv (4-week rolling average) reached 5.42% (TRx) and 5.47% (quantity) at the end of March. After a weak start in 2017 the market share have stabilized in March, and begun to show some signs to a positive trend.

Growth in the overall market (buprenorphine/naloxone) continues to strengthen, and showed a y/y growth rate of 11.2% (TRx) and of 10.3% (quantity), on a monthly basis, at the end of March.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-04-28 Update
2017-04-25 Update
2017-04-24 Update
2017-04-24 Update
2017-04-24 Update
2017-04-21 Update
2017-04-21 Update
2017-04-21 Update
2017-04-19 Update
2017-04-12 Update
2017-04-11 Update
2017-04-07 Update
2017-04-03 Update
2017-03-31 Update
2017-03-31 Analys
2017-03-30 Analys
2017-03-29 Update
2017-03-28 Update
2017-03-24 Update
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update